balance of significant experience with Diplomat and with other companies in the industry, including public companies.Growth StrategyWe plan to grow our business by continuing to execute on the following key growth strategies:Capitalize on track record to expand leadership positions in high-growth oncology and limited distribution markets.We believe
The remaining net proceeds of $50.0 million continue to be used for working capital and other general corporate purposes.AcquisitionsOn December 16, 2013, we acquired all of the outstanding stock of AHF, a specialty pharmacy focused on providing clotting
The results of operations for MedPro are included in our consolidated financial statements from the acquisition date.On February 26, 2015, we executed a definitive purchase agreement which provides that, upon the terms and conditions set forth therein, we will acquire all of the outstanding
anticipate our future revenues derived from specialty infusion pharmacy services will increase significantly as a percentage of total revenues as a result of such acquisitions.DebtOn June 26, 2014, we entered into an amended and restated credit agreement with GE Capital Bank, as agent, Comerica Bank, JP
net proceeds from this offering (including the net proceeds available in the event the underwriters exercise their option to purchase additional shares of our common stock from us) for debt repayment under the amended line of credit, working capital
Consolidated Financial Statements—Unaudited Pro Forma Consolidated Financial Information".14Table of ContentsFor the year ended December 31,2014Pro-Forma(1)2014(2)2013(3)2012(Dollars in thousands, except per share and per prescription data)(Unaudited)Consolidated Statements of Operations DataNet sales$2,485,898$2,214,956$1,515,139$1,126,943Cost of goods sold(2,269,915)(2,074,817)(1,426,112)(1,057,608)​​​​​​​​​​​​​​Gross profit215,983140,13989,02769,335Selling, general and administrative expenses(203,117)(127,556)(77,944)(64,392)​​​​​​​​​​​​​​Income from operations12,86612,58311,0834,943Interest expense(5,625)(2,528)(1,996)(1,086)Change in fair value of redeemable common shares—9,073(34,348)(6,566)Termination of existing stock redemption agreement(4,842)(4,842)——Equity loss and impairment of non-consolidated entity(6,208)(6,208)(1,055)(267)Other income1,2421,128196337​​​​​​​​​​​​​​Income (loss) before income taxes(2,567)9,206(26,120)(2,639)Income tax expense(4)(1,163)(4,655)——​​​​​​​​​​​​​​Net income (loss)(3,730)4,551(26,120)(2,639)Less: net loss attributable to noncontrolling interest(225)(225)——​​​​​​​​​​​​​​Net income (loss) attributable to Diplomat Pharmacy(3,505)4,776(26,120)(2,639)Net income allocable to preferred shareholders(16)—458——​​​​​​​​​​​​​​Net income (loss) allocable to common shareholders$(3,505)$4,318$(26,120)$(2,639)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Net income (loss) per common share(5):Basic$(0.06)$0.12$(0.79)$(0.08)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted$(0.06)$0.11$(0.79)$(0.08)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Weighted average common shares outstanding(5):Basic59,481,39135,990,12233,141,50033,141,500​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted59,481,39138,535,32533,141,50033,141,500​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Other Data (Unaudited)Adjusted EBITDA(6)$63,017$35,163$18,970$10,852Prescriptions dispensed(7)894,000797,000722,000680,000Prescriptions serviced (not dispensed)(8)212,000212,000208,000118,000​​​​​​​​​​​​​​Total prescriptions1,106,0001,009,000930,000798,000​​​​​​​​​​​​​​Net sales per prescription dispensed(9)$2,771$2,770$2,090$1,652Gross profit per prescription dispensed(10)$234$167$116$97Net sales per prescription serviced (not dispensed)(11)$27$27$27$29Gross profit per prescription serviced (not dispensed)(11)$27$27$27$29Adjusted EBITDA per prescription(12)$57$35$20$1415Table of ContentsAs of December 31,2014Pro-Forma(13)201420132012(Dollars in thousands)(Unaudited)Consolidated Balance Sheet DataProperty and equipment, net$14,447$13,150$12,378$12,634Total assets760,510390,086211,777139,595Total debt (including short-term debt and current portion of long-term debt)(14)(15)128,587—88,16463,102Total liabilities411,514221,359289,559191,157Shareholders' equity (deficit)(14)(16)348,996168,727(77,782)(51,562)(1)The
table below presents a reconciliation of net income (loss) attributable to the Company to Adjusted EBITDA for the periods indicated:For the year ended December 31,2014Pro-Forma201420132012(Dollars in thousands)(Unaudited)Net income (loss) attributable to Diplomat$(3,505)$4,776$(26,120)$(2,639)Depreciation and amortization30,4958,1393,9343,842Interest expense5,6252,5281,9961,086Income tax expense1,1634,655——​​​​​​​​​​​​​​EBITDA33,77820,098(20,190)2,289​​​​​​​​​​​​​​Share-based compensation expense(1)2,9542,871886915Change in fair value of redeemable common shares—(9,073)34,3486,566Restructuring and impairment charges(2)——1,033424Equity loss and impairment of non-consolidated entities(3)6,2086,2081,055267Severance and related fees(4)363363205412Contingent consideration and merger and acquisition related fees(5)12,2567,238677—Private company expenses(6)180180222—Other taxes and credits(7)1,0051,005—(148)Termination of existing stock redemption agreement4,8424,842——Other items(8)1,4311,431734127​​​​​​​​​​​​​​Adjusted EBITDA$63,017$35,163$18,970$10,852​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​(1)Share-based
In that event, the trading price of our common stock could decline and you could lose part or all of your investment.Risks Related to Our Business and IndustryOur failure to anticipate or appropriately adapt to changes or trends within the specialty pharmacy
of high cost specialty drugs could materially adversely impact our profitability, results of operations and financial condition.The continued efforts of health maintenance organizations, managed care organizations, pharmacy benefit managers, government programs
distribute could materially and adversely impact our volumes, net revenues, profitability and cash flows.Many healthcare companies have a presence in the specialty pharmacy market, and we expect a
significant increase in competition due to high growth anticipated in specialty drug spending, which could have a material and adverse impact on our business.There are a significant number of competitors that provide one or more comprehensive services, including distribution, with respect to
control and are difficult to predict, including the following:•the launch timing for specialty drugs;•the effect of the expiration of drug patents and the introduction of generic drugs;•the demand for the specialty drugs to which we have access;25Table of Contents•whether our expected distribution share of drugs that come to market is properly estimated;•whether revenues and margins on sales of drugs that come to market are properly estimated;•expenditures that we will or may incur to acquire or develop additional capabilities;•the timing of increases in drug costs by the manufacturers; and•changes in the reimbursement policies of payors.These
Accordingly, the combined company may not grow as quickly as we and the market expect, which could result in a decline of our stock price.In connection with the acquisition, we may incur significant additional indebtedness, which could
Changes in state and federal government regulation could restrict our ability to conduct our business and cause us to incur significant costs.The marketing, sale and purchase of pharmaceuticals and medical supplies and provision of healthcare services generally are extensively
statements:•our ability to adapt to changes or trends within the specialty pharmacy industry;•significant and increasing pricing pressure from third-party payors;•our relationships with key pharmaceutical manufacturers;•bad publicity about, or market withdrawal of, specialty drugs we dispense;•a significant increase in competition from a variety of companies in the health care industry;•our ability to expand the number of specialty drugs we dispense and related services;•maintaining existing patients;•revenue concentration of the top specialty drugs we dispense;•our ability to maintain relationships with a specified wholesaler and pharmaceutical manufacturer;•increasing consolidation in the healthcare industry;•managing our growth effectively;•limited experience with acquisitions;•our ability to complete the acquisition of BioRx on a timely basis or at all, and to recognize the expected benefits therefrom;•fluctuations in operating results;•failure or disruption of our information technology and security systems;•relationships with clinical experts and key thought leaders at U.S. physician groups and universities;41Table of Contents•reliance on a single shipping provider;•dependence on our senior management and key employees;•liability risks associated with our compounding services;•debt service obligations;•supply disruption of any of the specialty drugs we dispense;•loss of orphan drug status for such specialty drugs we dispense;•reductions of research, development and marketing of specialty drugs; and•other factors set forth under "Risk Factors."42Table of ContentsUSE OF PROCEEDSThe net proceeds available to us as a result of this offering will be approximately $116.0 million, based on an assumed public
Consolidated Financial Statements—Unaudited Pro Forma Combined Consolidated Financial Information."46Table of ContentsFor the year ended December 31,2014Pro-Forma(1)2014(2)2013(3)201220112010(Dollars in thousands, except per share and per prescription data)(Unaudited)Consolidated Statements of Operations DataNet sales$2,485,898$2,214,956$1,515,139$1,126,943$771,962$577,547Cost of goods sold(2,269,915)(2,074,817)(1,426,112)(1,057,608)(715,448)(536,451)​​​​​​​​​​​​​​​​​​​​Gross profit215,983140,13989,02769,33556,51441,096Selling, general and administrative expenses(203,117)(127,556)(77,944)(64,392)(47,434)(37,902)​​​​​​​​​​​​​​​​​​​​Income from operations12,86612,58311,0834,9439,0803,194Interest expense(5,625)(2,528)(1,996)(1,086)(598)(454)Change in fair value of redeemable common shares—9,073(34,348)(6,566)—(10,662)Termination of existing stock redemption agreement(4,842)(4,842)————Equity loss and impairment of non-consolidated entity(6,208)(6,208)(1,055)(267)(95)—Other income1,2421,12819633776485​​​​​​​​​​​​​​​​​​​​Income (loss) before income taxes(2,567)9,206(26,120)(2,639)9,151(7,837)Income tax expense(4)(1,163)(4,655)————​​​​​​​​​​​​​​​​​​​​Net income (loss)(3,730)4,551(26,120)(2,639)9,151(7,837)Less: net loss attributable to noncontrolling interest(225)(225)————​​​​​​​​​​​​​​​​​​​​Net income (loss) attributable to Diplomat Pharmacy(3,505)4,776(26,120)(2,639)9,151(7,837)Net income allocable to preferred shareholders(17)—458————​​​​​​​​​​​​​​​​​​​​Net income (loss) allocable to common shareholders$(3,505)$4,318$(26,120)$(2,639)$9,151$(7,837)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Net income (loss) per common share(5):Basic$(0.06)$0.12$(0.79)$(0.08)$0.28$(0.24)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted$(0.06)$0.11$(0.79)$(0.08)$0.27$(0.24)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Weighted average common shares outstanding(5):Basic59,481,39135,990,12233,141,50033,141,50033,141,50033,175,500​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted59,481,39138,535,32533,141,50033,141,50034,246,50033,175,500​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Other Data (unaudited)Adjusted EBITDA(6)$63,017$35,163$18,970$10,852$15,121$7,716Prescriptions dispensed(7)894,000797,000722,000680,000602,000580,000Prescriptions serviced (not dispensed)(8)212,000212,000208,000118,0007,000—​​​​​​​​​​​​​​​​​​​​Total prescriptions1,106,0001,009,000930,000798,000609,000580,000​​​​​​​​​​​​​​​​​​​​Net sales per prescription dispensed(9)$2,771$2,770$2,090$1,652$1,282$996Gross profit per prescription dispensed(10)$234$167$116$97$93$71Net sales per prescription serviced (not dispensed)(11)$27$27$27$29$49$—Gross profit per prescription serviced (not dispensed)(11)$27$27$27$29$49$—Adjusted EBITDA per prescription(12)$57$35$20$14$25$13Adjusted EPS(13)$0.59$0.49$(0.88)$(0.13)$0.17$(0.27)As of December 31,2014Pro-Forma(14)20142013201220112010(Dollars in thousands)(Unaudited)Consolidated Balance Sheet DataProperty and equipment, net$14,447$13,150$12,378$12,634$16,930$14,116Total assets760,510390,086211,777139,595100,38082,722Total debt (including short-term debt and current portion of long-term debt)(15)(16)128,587—88,16463,10212,94219,694Total liabilities411,514221,359289,559191,157130,471122,265Shareholders' (deficit) equity(15)(17)348,996168,727(77,782)(51,562)(30,091)(39,543)(1)The
are non-cash charges, the assets being depreciated/amortized will often have to be replaced in the future);•reflect interest expense on our debt and capital leases or interest income we earn on cash and cash equivalents;•reflect the amounts we paid in taxes or other components of our tax provision (which reduces cash available to us);•reflect certain expenses associated with our acquisition activities;•include the impact of share-based compensation (which is a recurring expense that will remain a key element of our long-term incentive
are non-cash charges, the assets being depreciated/amortized will often have to be replaced in the future);•reflect interest expense on our debt and capital leases or interest income we earn on cash and cash equivalents;•reflect the amounts we paid in taxes or other components of our tax provision (which reduces cash available to us);•reflect certain expenses associated with our acquisition activities;•include the impact of share-based compensation (which is a recurring expense that will remain a key element of our long-term incentive
table below presents a reconciliation of net income (loss) attributable to the Company to Adjusted EBITDA for the periods indicated:For the year ended December 31,2014Pro-Forma20142013201220112010(Dollars in thousands)(Unaudited)Net income (loss) attributable to Diplomat$(3,505)$4,776$(26,120)$(2,639)$9,151$(7,837)Depreciation and amortization30,4958,1393,9343,8423,0792,157Interest expense5,6252,5281,9961,086598454Income tax expense1,1634,655————​​​​​​​​​​​​​​​​​​​​EBITDA33,77820,098(20,190)2,28912,828(5,226)​​​​​​​​​​​​​​​​​​​​Share-based compensation expense(1)2,9542,8718869151,410839Change in fair value of redeemable common shares—(9,073)34,3486,566—10,662Restructuring and impairment charges(2)——1,0334244291,456Equity loss and impairment of non-consolidated entities(3)6,2086,2081,05526795—Severance and related fees(4)363363205412740—Contingent consideration and merger and acquisition related fees(5)12,2567,238677———Private company expenses(6)180180222———Other taxes and credits(7)1,0051,005—(148)(626)—Termination of existing stock redemption agreement4,8424,842————Other items(8)1,4311,431734127245(15)​​​​​​​​​​​​​​​​​​​​Adjusted EBITDA$63,017$35,163$18,970$10,852$15,121$7,716​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​(1)Share-based